Key clinical point: Non-Hispanic black patients with cancer and patients with hematologic malignancies have a significantly increased risk of death if they develop COVID-19.

Major finding: The adjusted odds ratios for mortality were 1.56 for non-Hispanic black vs. white patients and 1.80 for patients with hematologic malignancies vs. solid tumors.

Study details: Data from the CCC19 registry including 2,749 patients with COVID-19 and cancer.

Disclosures: The CCC19 registry is sponsored by Vanderbilt-Ingram Cancer Center. Dr. Rini disclosed relationships with Pfizer, Merck, Genentech/Roche, Aveo, AstraZeneca, Bristol Myers Squibb, Exelixis, Synthorx, Peloton, Compugen, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, and PTC Therapeutics.